Skip to main content
. 2020 Feb 17;77(5):1–11. doi: 10.1001/jamaneurol.2019.5125

Figure 3. Categorical End Points.

Figure 3.

A, Responder analysis for Quantitative Myasthenia Gravis (QMG) score with 0.3-mg/kg zilucoplan daily subcutaneously. B, Minimal symptom expression (MSE), defined as Myasthenia Gravis Activities of Daily Living score of 0 or 1 at 12 weeks. C, Patients who received treatment with rescue therapy with intravenous immunoglobulin or plasma exchange.